2013 Fiscal Year Final Research Report
The identification of drug resistance in ovarian cancer : new insights form metabolomics and autophagy
| Project/Area Number |
22390308
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Yamagata University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAKAHASHI Toshifumi 山形大学, 医学部, 講師 (20302292)
OHTA Tsuyoshi 山形大学, 医学部, 助教 (50375341)
TAKATA Keiko 山形大学, 医学部, 助教 (平成22 年度) (70375343)
SUTOH Takeshi 山形大学, 医学部, 助教 (70466605)
MABUCHI Seiji 大阪大学, 医学部, 助教 (00452441)
SAWADA Kenjiro 大阪大学, 医学部, 講師 (00452392)
|
|---|
| Project Period (FY) |
2010-04-01 – 2014-03-31
|
| Keywords | 卵巣がん / 薬剤耐性化 / Rho/ROCK経路 / EGF受容体 / Trabectedin / ハニカム膜 / mTOR / メタボローム解析 |
|---|
| Research Abstract |
We identified that the anti-tumor activity of trabectedin was greater than any other existing anti-cancer agents, indicating that trabectedin is a promising agent for ovarian clear cell carcinoma (CCC). We also identified that combination treatment with trabectedin and irinotecan or topotecan displays the greatest cytotoxic effect against ovarian CCC. We believe that our studies provide the rationale for future clinical trials of trabectedin-based combination chemotehrapies in patients with ovarian CCC. We are currently investigating the role of autophagy in the sensitivity of CCC cells to trabectedin-based combination chemotherapies. We also identified that high levels of WT1 expression correlated with aggressive clinical features in ovarian cancer. The median disease-free survival time in patients with high WT1 expression levels was significantly shorter (p=0.038) than that in patients with low WT1 expression.
|
Research Products
(21 results)
